Dietary supplementation with the n-3 polyunsaturated fatty acids (n-3 PUFA) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) to rats preconditions the liver against ischemia-reperfusion (IR) injury, with reduction of the enhanced nuclear factor-κB (NF-κB) functionality occurring in the early phase of IR injury, and recovery of IR-induced pro-inflammatory cytokine response. The aim of ...

OBJECTIVES The peroxisome proliferator-activated receptor-α (PPAR-α) has attracted considerable attention for its anti-inflammatory properties; however, Toll-like receptor (TLR) pathways have an essential proinflammatory role in acute pancreatitis (AP). This study aimed to evaluate the attenuation of inflammation by PPAR-α and to investigate the interaction between PPAR-α and TLR pathways in AP...

AIMS To compare the molecular and biologic signatures of a balanced dual peroxisome proliferator-activated receptor (PPAR)-α/γ agonist, aleglitazar, with tesaglitazar (a dual PPAR-α/γ agonist) or a combination of pioglitazone (Pio; PPAR-γ agonist) and fenofibrate (Feno; PPAR-α agonist) in human hepatocytes. METHODS AND RESULTS Gene expression microarray profiles were obtained from primary hum...

OBJECTIVE Dipeptidyl peptidase (DPP)-4 is responsible for the degradation of several peptides that contain an alanine or proline at the penultimate position or position P1. DPP-4 inhibitors (DPP-4is) have protective effects against type-2 diabetes and several metabolic disorders. METHODS In the present study, we examined the effects of des-fluoro-sitagliptin (DFS), a DDP-4i, on body adiposity...

SCOPE A natural carotenoid abundant in seafood, astaxanthin (AX), has hypolipidemic activity, but its underlying mechanisms of action and protein targets are unknown. We investigated the molecular mechanism of action of AX in hepatic hyperlipidemia by measuring peroxisome proliferator-activated receptors (PPAR) activity. METHODS AND RESULTS We examined the binding of AX to PPAR subtypes and i...

INTRODUCTION The present study aimed to investigate the relationship between serum peroxisome proliferator-activated receptor-γ (PPAR-γ) protein concentration and inflammatory markers in elderly patients with atrial fibrillation (AF). MATERIAL AND METHODS We enrolled a total of 73 elderly patients: 45 with AF as the test group and 28 in sinus rhythm as a control group. We assayed serum PPAR-γ...

In the present study, we investigated the effects of apolipoprotein A-I (apoA-I) on matrix metalloproteinase-2 (MMP-2) expression in vivo and in vitro. First, we detected the effects of apoA-I on aorta MMP-2, peroxisome proliferator-activated receptor α/γ (PPAR α/γ), cyclooxygenase-2 (COX-2), and nuclear factor kappa B (NF-κB) expressions in atherosclerotic rabbit models using immunohistochemic...

Peroxisome proliferator-activated receptor (PPAR)-α, a member of a large nuclear receptor superfamily, plays a major role in the regulation of lipid metabolism. Recently, PPARα activation has been shown to confer additional benefits on endothelial function, kidney function, and anti-inflammation, suggesting that PPARα agonists may be good candidates for treating acute renal failure. In clinical...


 Purpose: To determine the effect of diosmetin on young, non-alcoholic fatty liver disease (NAFLD) rats.
 Methods: Five groups SD rats were used: control group, high-fat diet low-dose medium-dose and high-dose each with 10 rats. After 3 months, interleukin 6 (IL-6), IL-1β) TNF-α) assayed. Protein expressions p-AMPKα, CPT-1 PPAR-α, AMPKα, SREBP-1c FAS assayed.
 Results: In levels...

PURPOSE We investigated the mRNA levels of peroxisome proliferator-activated receptor (PPAR)-α, PPAR-γ, adipokines, and cytokines in the lung tissue of lean and obese mice with and without ovalbumin (OVA) challenge, and the effect of rosiglitazone, a PPAR-γ agonist. METHODS We developed 6 mice models: OVA-challenged lean mice with and without rosiglitazone; obese mice with and without rosigli...